Merck Receives Positive CHMP Opinion for KEYTRUDA® in Combination Therapy for First-Line Treatment of Non-Epithelioid Mesothelioma

Australia Launches Genomics Australia to Lead Advances in Genomic Medicine

Sidra Medicine Unveils Masterclasses Ahead of PMFG 2024 Summit

FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

CHMP Recommends Approval of Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

Home
/
insight
/
details

Revolutionizing Radiation Therapy: Strategic Partnerships and Innovative Technologies

NextEdge Admin

06 May 2024

3 min 36 sec

Elekta, a pioneering force in precision radiation therapy, is committed to ensuring optimal cancer care for every patient. With a focus on collaboration and innovation, Elekta is dedicated to developing sustainable, outcome-driven, and cost-effective solutions that meet the evolving needs of patients worldwide. Headquartered in Stockholm, Sweden, and with a presence in over 40 countries, Elekta is listed on Nasdaq Stockholm and is reshaping the landscape of cancer treatment globally.

In a strategic move to advance comprehensive and personalized cancer care, Elekta entered into a non-exclusive partnership with Royal Philips in 2021. This partnership aims to leverage advanced informatics and image-guided radiation therapy (RT) solutions to deliver superior diagnosis and adaptive, personalized treatments for clinicians, shorter treatment times, and more precise therapy for patients, ultimately reducing costs for healthcare providers.

Royal Philips, a prominent health technology firm, shares Elekta’s commitment to improving health outcomes and quality of life. With expertise spanning from healthy living and prevention to diagnosis, treatment, and home care, Philips utilizes advanced technology and deep clinical insights to deliver integrated solutions across various healthcare domains.

In 2023, Elekta expanded its reach in India through collaboration with GE HealthCare, addressing the pressing need for access to precision radiation therapy solutions. By combining GE HealthCare’s diagnostic solutions with Elekta’s radiation therapy offerings, hospitals in India can now provide comprehensive cancer care services, bridging the gap in access to quality treatment.

Elekta’s groundbreaking innovation, Elekta Unity MR-Linac, represents a paradigm shift in radiation therapy. By integrating diagnostic-quality MR imaging with a linear accelerator, Elekta Unity enables clinicians to visualize tumors during treatment, leading to more precise and effective therapy. With features like Comprehensive Motion Management (CMM) and True Tracking, Elekta Unity enhances treatment outcomes by reducing side effects and improving patient experiences.

Among recent technological advancements, Magnetic Resonance Imaging (MRI) guided radiotherapy (MRgRT) stands out for its potential to revolutionize image-guided radiation delivery. With real-time imaging, motion management, and adaptive treatment planning capabilities, MRI-guided linear accelerators offer unprecedented precision and flexibility in cancer treatment.

Elekta’s strategic partnerships and innovative technologies underscore its commitment to transforming cancer care globally, ensuring that every patient receives the highest quality and most personalized treatment possible.